LD-2 disclosure · 4th Quarter - Report
ENDO PHARMACEUTICALS INC.
Client
- Name
- ENDO PHARMACEUTICALS INC.
- Description
- Speciality healthcare solutions company.
- Location
- District of Columbia · United States of America
Registrant
- Description
- ​Government Affairs Consulting Firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesHealth Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market. H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016. S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Lobbyistsmr JOSEPH H GIBSON
Covered position (mr JOSEPH H GIBSON): Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997
TargetedHOUSE OF REPRESENTATIVES
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research. H.R. 160: Protect Medical Innovation Act of 2015. Tax treatment of inverted companies. Tax issues in mergers and acquisitions of US firms.